Anti-αvβ3 Integrin Recombinant Antibody (Etaracizumab/Etaratuzumab/Medi-522) (CAT#: TAB-705)

Recombinant humanized (from mouse) antibody expressed in CHO binding to human αVβ3 integrin. Etaracizumab is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer, ovarian cancer and various other types of cancer.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Datasheet
  • MSDS
  • Publications
  • COA
ELISA

Figure 1 Serum MEDI-522 concentrations.

Figure 1 Serum MEDI-522 concentrations.

Serum concentrations of MEDI-522 were determined by ELISA at multiple time points for each patient over the first 8 weeks. Points, means of MEDI-522 serum concentrations per dose cohort at each time point collected; bars, SD.

McNeel, D. G., Eickhoff, J., Lee, F. T., King, D. M., Alberti, D., Thomas, J. P.,... & Zhang, J. (2005). Phase I trial of a monoclonal antibody specific for αvβ3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clinical Cancer Research, 11(21), 7851-7860.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG2 - kappa
  • Species Reactivity
  • Human
  • Applications
  • FC, IP, ELISA, Neut, FuncS, IF, IHC
  • Trade name
  • abegrin
  • CAS
  • 892553-42-3
  • Generic Name
  • etaracizumab/etaratuzumab/MEDI-522
  • UNII
  • 41W9MFI160
  • MW
  • 144.3 kDa

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Storage
  • Store it under sterile conditions at -20°C upon receiving. Recommend to pack the protein into smaller quantities for optimal storage.

Applications

  • Application Notes
  • The αVβ3 integrin antibody has been reported in applications of FC, IP, ELISA, Neut, FuncS, IF, IHC.

Target

  • Alternative Names
  • etaracizumab/etaratuzumab/MEDI-522;abegrin;892553-42-3;Etaratuzumab;MEDI-522;Abegrin;αVβ3

Related Resources

  • Biosimilar Overview
Please refer to Etaracizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Etaracizumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "αVβ3 integrin"

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-705 Afuco™ Anti-αVβ3 Integrin ADCC Recombinant Antibody (Etaracizumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody

scFv Fragment Antibody

Fab Fragment Antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-705. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare